Biogen Presents Optimistic Outcomes from Section 2 IGNAZ Examine of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024 By Investing.com
The detailed examine outcomes confirmed interim findings, exhibiting secure kidney perform and…
Foresee Prescribed drugs Proclaims Preliminary Outcomes from a Part 1 Scientific Trial, Highlighting Promising Security, Tolerability and Pharmacokinetic Profile of Linvemastat (FP-020), a Novel and Choose By Investing.com
TAIPEI, Oct. 20, 2024 /PRNewswire/ -- Foresee Prescribed drugs (TPEx: 6576), ("Foresee")…
Benitec Biopharma Reviews Optimistic Knowledge from Two Topics Handled with Low-Dose BB-301 in Section 1b/2a Research Introduced at twenty ninth Annual Congress of the World Muscle Society By Investing.com
-Topic 1 and Topic 2 skilled sturdy, clinically significant enhancements in swallowing…
Registrational Section III Research of APG-2449 Cleared by China CDE for the Therapy of Sufferers with NSCLC By Investing.com
ROCKVILLE, Md. and SUZHOU, China, Oct. 7, 2024 /PRNewswire/ -- Ascentage Pharma…
Longboard begins world Section 3 trial for Dravet syndrome drug By Investing.com
LA JOLLA, Calif. - Longboard Prescription drugs, Inc. (NASDAQ:LBPH) has launched a…
Black Diamond Therapeutics to Host Webcast Presentation of Preliminary Part 2 BDTX-1535 Information in Sufferers With Recurrent EGFRm NSCLC By Investing.com
Webcast to be held Monday, September 23, at 8:00 a.m. ET CAMBRIDGE,…
Pfizer Presents Optimistic Information from Section 2 Examine of Ponsegromab in Sufferers with Most cancers Cachexia By Investing.com
Examine met main endpoint of change from baseline in physique weight for…
Moberg Pharma lowers expectations on main endpoint in ongoing section 3 trial following information in a subset of sufferers By Investing.com
STOCKHOLM, Sept. 13, 2024 /PRNewswire/ -- Moberg Pharma AB (OMX: MOB) broadcasts…
Longboard Prescription drugs Broadcasts Optimistic Interim Evaluation Outcomes from the Open-Label Extension (OLE) of the Part 1b/2a PACIFIC Examine Evaluating Bexicaserin in Members with Developmental and By Investing.com
Bexicaserin achieved an general median seizure discount of 57.7% in countable motor…
Ifinatamab Deruxtecan Continues to Display Promising Goal Response Charges in Sufferers with Intensive-Stage Small Cell Lung Most cancers in IDeate-Lung01 Part 2 Trial By Investing.com
Goal response price of 54.8% seen with Daiichi Sankyo and Merck's ifinatamab…
